Pfizer (PFE) activist investor Starboard Value did not nominate any directors to the drugmaker's board ahead of its annual meeting in April, Bloomberg reported Monday, citing people familiar with the matter.
The development offers temporary relief to Pfizer amid concerns raised by Starboard regarding acquisitions and investments, according to the report.
But Starboard, which acquired a roughly $1 billion stake in Pfizer last year, could push for board changes in 2026 if they fail to reach a prior settlement agreement, the report said.
Neither Pfizer nor Starboard immediately replied to MT Newswires' requests for comment.
Shares of Pfizer were up more than 2% in recent trading.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 26.70, Change: +0.61, Percent Change: +2.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。